Saxagliptin (2) – Onglyza®
Diabetes mellitus type 2, monotherapy
Characteristics
| Start date | 01.09.2013 |
|---|---|
| Resolution | 17.04.2014 |
| INN | Saxagliptin |
| Brand name | Onglyza® |
| Pharm. company |
Dossier: Bristol-Myers Squibb GmbH & Co. KGaA und AstraZeneca GmbH
New distributor: AstraZeneca GmbH |
| G-BA Procedure ID | D-072 |
| ATC code | A10BH03 DPP-4 inhibitors (A10BH) |
| DDD | 5 mg O |
| Therapeutic area | Metabolic diseases Diabetes mellitus (DM type 1-2) |
| Reason for procedure | not completed: discontinued |
Associated procedures
| Saxagliptin (3) | Onglyza® | AstraZeneca GmbH | Diabetes mellitus type 2, combination therapy | 1,182,900–1,382,900 | 100% additional benefit not proven | |
| Saxagliptin (2) | Onglyza® | Bristol-Myers Squibb GmbH & Co. KGaA und AstraZeneca GmbH | Diabetes mellitus type 2, monotherapy | n.d. | discontinued | |
| Saxagliptin (1) | Onglyza® | Bristol-Myers Squibb GmbH & Co. KGaA / AstraZeneca GmbH | Diabetes mellitus type 2, combination therapy |
0
1,182,900–1,382,900 |
50% Hint for minor additional benefit repealed |
<< List of all resolutions